Drug‐specific cyclodextrins with emphasis on sugammadex, the neuromuscular blocker rocuronium and perioperative anaphylaxis: implications for drug allergy
Authors:
- 7 July 2011
- journal article
- review article
- Published by Wiley in Clinical & Experimental Allergy
- Vol. 41 (12) , 1663-1678
Abstract
Cyclodextrins, oligosaccharides linked in a circular arrangement around a central cavity, are used extensively in the pharmaceutical industry to improve drug delivery. Their usefulness depends on their capacity to form a drug inclusion, or host-guest, complex within the cavity. In an attempt to improve the delivery of the widely used neuromuscular blocking drug (NMBD) rocuronium, a rocuronium inclusion complex was formed with a chemically modified γ-cyclodextrin. The high binding affinity and specificity of the modified carrier (named sugammadex) for rocuronium (and other aminosteroid NMBDs) led to its use in anaesthesia as an innovative and useful agent for rapid reversal of rocuronium-induced neuromuscular block by sequestering the drug as an inclusion complex. This, in turn, led to the suggestion that sugammadex might be useful to remove the NMBD from the circulation of patients experiencing rocuronium-induced anaphylaxis, a suggestion subsequently supported in case reports where traditional treatment had failed. Successful resuscitations suggested that sugammadex might be a valuable new treatment for such intractable cases but, given the inappropriateness of clinical trials, confirmation or refutation will have to await the slow accumulation of results of individual case reports. Important questions related to antibody accessibility of drug allergenic structures on the rocuronium-sugammadex inclusion complex, and the competition between sugammadex and IgE antibodies (both free and cell bound) for rocuronium, also remain and can be investigated in vitro. The sugammadex findings indicate that the use of carrier molecules such as the cyclodextrins to improve drug delivery will sometimes give rise to changed immunologic and allergenic behaviour of some drugs and this will have to be taken into account in preclinical drug safety assessments of drug-carrier complexes. The possibility of encapsulating and removing other allergenic drugs, e.g., penicillins and cephalosporins, in cases of difficult-to-reverse anaphylaxis to these drugs is discussed.Keywords
This publication has 97 references indexed in Scilit:
- On the origin and specificity of antibodies to neuromuscular blocking (muscle relaxant) drugs: an immunochemical perspectiveClinical & Experimental Allergy, 2009
- Suspected Anaphylactic Reactions Associated with AnaesthesiaAnaesthesia, 2009
- Effect of β-cyclodextrin and hydroxypropyl β-cyclodextrin complexation on physicochemical properties and antimicrobial activity of cefdinirJournal of Pharmaceutical and Biomedical Analysis, 2008
- Discovery, development, and clinical application of sugammadex sodium, a selective relaxant binding agentDrug Design, Development and Therapy, 2008
- Pholcodine stimulates a dramatic increase of IgE in IgE‐sensitized individuals. A pilot studyAllergy, 2005
- Prevention of Anaphylactic Reactions to Anaesthetic DrugsDrug Safety, 2004
- Tryptase Levels as an Indicator of Mast-Cell Activation in Systemic Anaphylaxis and MastocytosisNew England Journal of Medicine, 1987
- The Conversion of Starch to Crystalline Dextrins by the Action of a New Type of Amylase Separated from Cultures of Aerobacillus maceransJournal of the American Chemical Society, 1939
- Über die Schardinger ‐ Dextrine aus StärkeBerichte der deutschen chemischen Gesellschaft (A and B Series), 1938
- Über thermophile Bakterien aus verschiedenen Speisen und MilchEuropean Food Research and Technology, 1903